Reviews in clinical and experimental hematology最新文献_第2页

Supportive care including growth factors in myelodysplastic syndromes. 支持治疗包括骨髓增生异常综合征中的生长因子。

Reviews in clinical and experimental hematology Pub Date : 2004-12-01

Claude Gardin, Pierre Fenaux

{"title":"Supportive care including growth factors in myelodysplastic syndromes.","authors":"Claude Gardin, Pierre Fenaux","doi":"","DOIUrl":"","url":null,"abstract":"In spite of recent advances in the treatment of myelodysplastic syndromes (MDS), supportive care remains a very important part of the therapy. Red blood cells transfusions are the most important component of this supportive care. They transiently relieve anemia symptoms and alleviate their effects on quality of life and daily functioning. Platelet transfusion therapy is less frequently needed, at least in low-risk MDS. Dealing with an increased risk of infections linked to neutropenia, mainly by broad spectrum antibiotics, is also needed, more often in advanced stages of [dict: MDS] or when the MDS evolves to acute myeloid leukemia. Chronic red blood cell transfusions expose patients to various side-effects, including blood components intolerance reactions and alloimmunization risks, but also increased frequency of iron overload, a more significant problem in low-risk heavily transfused MDS patients, who have prolonged life expectancy. The use of growth factors is becoming a more and more important part of current supportive care. High-dose erythropoietin is able to reduce or suppress red blood cell transfusions needs in selected subgroups of MDS. The short-term use of granulocyte colony-stimulating factor is also often proposed in infections, although not formally established by prospective trials. Although trials of growth factors with thrombopoeitic activity have been performed with interleukin 11 and are underway with thrombopoeitin, none of them are available for routine use.","PeriodicalId":82483,"journal":{"name":"Reviews in clinical and experimental hematology","volume":"8 2","pages":"E3"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25198009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes. 骨髓增生综合征的新兴治疗和支持性护理方法。

Reviews in clinical and experimental hematology Pub Date : 2004-12-01

Ghulam J Mufti

引用次数: 0

Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes. 预测骨髓增生异常综合征患者预后的预后指标和评分系统。

Reviews in clinical and experimental hematology Pub Date : 2004-12-01

Carlo Aul, Aristoteles Giagounidis, Michael Heinsch, Ulrich Germing, Arnold Ganser

{"title":"Prognostic indicators and scoring systems for predicting outcome in patients with myelodysplastic syndromes.","authors":"Carlo Aul, Aristoteles Giagounidis, Michael Heinsch, Ulrich Germing, Arnold Ganser","doi":"","DOIUrl":"","url":null,"abstract":"A number of clinical, laboratory, morphological and genetic factors are useful to predict the natural course of Myelodysplastic syndromes (MDS). The identification of these factors resulted in the development of scoring systems that aid to differentiate high risk patients from those with a better prognosis. At the initial approach towards a patient with MDS the clinician will take into account the individual's age and performance score, and the morphological characteristics of the peripheral blood and bone marrow, including number of dysplastic lineages and blast count, as proposed by the new World Health Organization classification. Some laboratory features like the neutrophil and platelet count and the lactate dehydrogenase levels are of additional independent prognostic importance. Finally, the karyotype of the malignant hematopoietic cells is a very strong prognostic variable and therefore mandatory in the assessment of patients with MDS. By using part of the above-mentioned factors, the International Prognostic Scoring System has proven reliable in grouping MDS patients into one of four risk categories and can be used in the stratification of patients in therapeutic trials. With the avenue of more sophisticated molecular techniques like gene expression profiling, it might become possible not only to predict the natural course of the disease more precisely, but also to identify patient populations that are prone to respond to specific drugs especially designed for specific genetic lesions.","PeriodicalId":82483,"journal":{"name":"Reviews in clinical and experimental hematology","volume":"8 2","pages":"E1"},"PeriodicalIF":0.0,"publicationDate":"2004-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25196289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombotic problems in hematologic malignancies. 血液恶性肿瘤的血栓形成问题。